Delivery Order SPE2DB22D6029-SPE2DB25FLVEA
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,288.86 to AmerisourceBergen Drug Corp for the supply of Envarsus XR 1 mg tablets (100-count packaging). This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive $999.99 billion pharmaceutical supply vehicle supporting military healthcare programs globally through December 2026....
- The Defense Logistics Agency awarded a delivery order valued at $3,423.90 to AmerisourceBergen Drug Corp for the supply of Envarsus XR 4 mg tablets (100-count bottles) on August 25, 2025, with completion scheduled for September 16, 2025. This firm fixed-price delivery order represents a non-set-aside competitive award to the pharmaceutical distributor's corporate office in Conshohocken, Pennsylvania. The contract is issued as a child order under AmerisourceBergen's larger Indefinite Delivery...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order on May 8, 2025, by the Defense Logistics Agency's Medical Supply Chain to supply Envarsus XR 1 mg tablets (30-count) at a ceiling value of $1,553.40. The contract is a firm fixed-price delivery order with an ultimate completion date of May 30, 2025, and was competitively awarded without set-aside designation. This award represents a child contract under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,581.30 to AmerisourceBergen Drug Corp for the supply of Envarsus XR 1 mg tablets (100-count package) under a firm fixed-price contract. The order was competitively awarded without a set-aside designation and is scheduled for completion by September 15, 2025. AmerisourceBergen will fulfill this requirement from its corporate office location in Conshohocken, Pennsylvania, where the company is headquartered as a major...
- The Defense Logistics Agency awarded a delivery order valued at $1,718.48 to AmerisourceBergen Drug Corp for the supply of Envarsus XR 1 mg tablets (100-count units) on August 7, 2025, with completion expected by August 28, 2025. This firm fixed price delivery order represents a non-set-aside competitive award to the pharmaceutical distributor's Corporate Office division, with performance to be executed from the company's Conshohocken, Pennsylvania headquarters. The contract falls under...
- The Defense Logistics Agency awarded a $2,577.72 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Envarsus XR 1 mg tablets (100-unit quantity), with an ultimate completion date of October 7, 2025. This non-set-aside competitive award is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract action under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a $1,711.95 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Envarsus XR 4 mg tablets (100-count units). This is a non-set-aside competitive award with an ultimate completion date of September 4, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly for military and veteran...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Envarsus XR 1 mg tablets in a quantity of 100 units. This competitively awarded, non-set-aside contract carries a ceiling value of $1,718.48 with firm fixed pricing and is scheduled for completion by September 11, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Envarsus XR 1 mg tablets (100-count units) with a contract ceiling value of $1,288.86. This firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December 2026. The award utilized no set-aside designation and was...
- The U.S. Department of Defense's Medical Supply Chain awarded a delivery order valued at $5,135.85 to AmerisourceBergen Drug Corp for the supply of Envarsus XR 4 mg tablets (100-count units) on August 22, 2025, with an ultimate completion date of September 15, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child...
- SPE2DB22D6029Indefinite Delivery Contract
- SPE2DB22D6029-SPE2DB25FLVEADelivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,035.60 to AmerisourceBergen Drug Corp for the supply of Envarsus XR 1 mg tablets (30-count packaging). This competitively awarded, non-set-aside contract utilizes firm fixed price pricing and is scheduled for completion by June 23, 2025. The order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vehicle running through December 2026 that serves as a comprehensive global pharmaceutical support mechanism for military healthcare programs. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly for military and veteran healthcare systems. The company's federal contract portfolio demonstrates extensive experience delivering a comprehensive range of pharmaceutical products and medical supplies across multiple therapeutic domains, including specialty medications, brand-name and generic drugs, vaccines, and medical devices. This delivery order for Envarsus XR, a tacrolimus-based immunosuppressant medication, exemplifies the company's role in supporting the Defense Health Agency and other government healthcare systems through flexible, competitive contract vehicles.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.0k | 5/30/25 |